Acumen Pharmaceuticals (ABOS) Corporate presentation summary

Market opportunity and disease landscape

• Early Alzheimer's disease represents a significant and expanding market, driven by an aging population and improved early diagnosis through blood-based biomarkers.

• Current anti-amyloid therapies are gaining traction, but there is a need for treatments with improved efficacy, safety, and convenience, especially those targeting earlier disease stages.

Pipeline and clinical development

• Sabirnetug (ACU193) is a monoclonal antibody highly selective for toxic amyloid beta oligomers (ABOs), with positive Phase 1 results and Phase 2 topline data expected in late 2026.

• The ALTITUDE-AD Phase 2 trial is fully enrolled (n=542), with topline results anticipated in late 2026 and an open-label extension underway.

• A subcutaneous formulation of sabirnetug has shown favorable pharmacokinetics and safety in healthy volunteers, supporting further development for more convenient dosing.

Scientific rationale and differentiation

• Sabirnetug demonstrates high selectivity for ABOs over monomers and plaques, binding a broad range of oligomeric species and showing minimal off-target effects.

• Phase 1 data show dose-dependent target engagement, significant improvements in CSF and plasma biomarkers, and robust amyloid plaque reduction comparable to leading therapies.

• Safety profile is compelling, with a low incidence of ARIA-E and no cases in ApoE4 homozygotes, suggesting a broad therapeutic index.